Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation

• Status: Completed
• Trial end date: 2019-06-15
• Target enrollment: 0
• Participant gender: All

Summary

Tocilizumab will be administered prior to transplantation in order to prevent the onset of cytokine release syndrome and its complications associated to peripheral blood haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitario Dr. Jose E. Gonzalez

Criteria

Inclusion Criteria:

• Haploidentical transplant recipients

• Informed consent signature

• Previous diagnosis of any neoplastic, metabolic or autoimmune disease

Exclusion Criteria:

• History of immune deficiency virus infection

• Hepatitis C or B virus infection

• Documented bacterial of fungal infection prior to tocilizumab infusion

• Previous use of tocilizumab